KM1 / Shenzhen Hua Yao Kang Ming Biopharma - LARVOL DELTA

A single arm, open clinical study to evaluate the safety, tolerance and initial efficacy of KM1 oncolytic vaccinia virus injection in the treatment of high-risk patients with recurrent non muscle invasive bladder cancer (ChiCTR) - P1 | N=18 | Recruiting | Sponsor: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of | Not yet recruiting ➔ Recruiting

Enrollment open • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

K19017-004: Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Tongji Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Oncolytic virus • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor